den Brok WD, Speers CH, Gondara L, Baxter E, Tyldesley SK, Lohrisch CA. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res Treat. 2017;161(3):549–56. https://doi.org/10.1007/s10549-016-4080-9.

Article  Google Scholar 

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72. https://doi.org/10.1016/S0140-6736(13)62422-8.

Article  PubMed  Google Scholar 

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. KEYNOTE-522 Investigators. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556–67. https://doi.org/10.1056/NEJMoa2112651.

Article  CAS  PubMed  Google Scholar 

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21. https://doi.org/10.1038/nature12477.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50. https://doi.org/10.1016/S1470-2045(17)30904-X.

Article  PubMed  Google Scholar 

O’Loughlin M, Andreu X, Bianchi S, Chemielik E, Cordoba A, Cserni G, et al. Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study. Breast Cancer Res Treat. 2018;171(1):1–9. https://doi.org/10.1007/s10549-018-4825-8.

Article  PubMed  Google Scholar 

Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017;19(1):2. https://doi.org/10.1186/s13058-016-0794-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miyagawa Y, Araki K, Bun A, Ozawa H, Fujimoto Y, Higuchi T, et al. Significant association between low baseline neutrophil-to-lymphocyte ratio and improved progression-free survival of patients with locally advanced or metastatic breast cancer treated with eribulin but not with nab-paclitaxel. Clin Breast Cancer. 2018;18(5):400–9. https://doi.org/10.1016/j.clbc.2018.03.002.

Article  CAS  PubMed  Google Scholar 

Pang J, Zhou H, Dong X, Wang S, Xiao Z. Relationship between the neutrophil to lymphocyte ratio, stromal tumor-infiltrating lymphocytes, and the prognosis and response to neoadjuvant chemotherapy in triple-negative breast cancer. Clin Breast Cancer. 2021;21(6):e681–7. https://doi.org/10.1016/j.clbc.2021.04.004.

Article  CAS  PubMed  Google Scholar 

Chae S, Kang KM, Kim HJ, Kang E, Park SY, Kim JH, et al. Neutrophil–lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer. Curr Oncol. 2018;25(2):e113–9. https://doi.org/10.3747/co.25.3888.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajiri H, Takashima T, et al. Predictive value of neutrophil/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer. Ann Surg Oncol. 2016;23(4):1104–10. https://doi.org/10.1245/s10434-015-4934-0.

Article  PubMed  Google Scholar 

Wu Q, Ma G, Deng Y, Luo W, Zhao Y, Li W, et al. Prognostic value of Ki-67 in patients with resected triple-negative breast cancer: a meta-analysis. Front Oncol. 2019;9:1068. https://doi.org/10.3389/fonc.2019.01068.

Article  PubMed  PubMed Central  Google Scholar 

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. International TILs Working Group 2014 The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259–71. https://doi.org/10.1093/annonc/mdu450.

Article  CAS  PubMed  Google Scholar 

Kobayashi K, Horii R, Ito Y, Miyagi Y, Ohno S, Iwase T, et al. Prognostic significance of histological therapeutic effect in preoperative chemotherapy for breast cancer. Pathol Int. 2016;66(1):8–14. https://doi.org/10.1111/pin.12365.

Article  PubMed  Google Scholar 

Mukai H, Arihiro K, Shimizu C, Masuda N, Miyagi Y, Yamaguchi T, et al. Stratifying the outcome after neoadjuvant treatment using pathological response classification by the Japanese Breast Cancer Society. Breast Cancer. 2016;23(1):73–7. https://doi.org/10.1007/s12282-015-0640-9.

Article  PubMed  Google Scholar 

Petekkaya I, Unlu O, Roach EC, Gecmez G, Okoh AK, Babacan T, et al. Prognostic role of inflammatory biomarkers in metastatic breast cancer. J BUON. 2017;22(3):614–22.

PubMed  Google Scholar 

Gao G, Wang Z, Qu X, Zhang Z. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer. 2020;20(1):179. https://doi.org/10.1186/s12885-020-6668-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lusho S, Durando X, Mouret-Reynier MA, Kossai M, Lacrampe N, Molnar I, et al. Platelet-to-lymphocyte ratio is associated with favorable response to neoadjuvant chemotherapy in triple negative breast cancer: a study on 120 patients. Front Oncol. 2021;11:678315. https://doi.org/10.3389/fonc.2021.678315.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25(3):611–8. https://doi.org/10.1093/annonc/mdt556.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Galvez M, Castaneda CA, Sanchez J, Castillo M, Rebaza LP, Calderon G, et al. Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy. World J Clin Oncol. 2018;9(2):33–41. https://doi.org/10.5306/wjco.v9.i2.33.

Article  PubMed  PubMed Central  Google Scholar 

Hida AI, Sagara Y, Yotsumoto D, Kanemitsu S, Kawano J, Baba S, et al. Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between triple-negative and HER2-positive breast cancers treated with standard systemic therapies. Breast Cancer Res Treat. 2016;158(1):1–9. https://doi.org/10.1007/s10549-016-3848-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747–56. https://doi.org/10.1016/S1470-2045(14)70160-3.

Article  CAS  Google Scholar 

Russo L, Maltese A, Betancourt L, Romero G, Cialoni D, De la Fuente L, et al. Locally advanced breast cancer: tumor-infiltrating lymphocytes as a predictive factor of response to neoadjuvant chemotherapy. Eur J Surg Oncol. 2019;45(6):963–8. https://doi.org/10.1016/j.ejso.2019.01.222.

Article  PubMed  Google Scholar 

Mori H, Kubo M, Yamaguchi R, Nishimura R, Osako T, Arima N, et al. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Oncotarget. 2017;8(9):15584–92. https://doi.org/10.18632/oncotarget.14698.

Article  PubMed  PubMed Central  Google Scholar 

Park HS, Heo I, Kim JY, Kim S, Nam S, Park S, et al. No effect of tumor-infiltrating lymphocytes (TILs) on prognosis in patients with early triple-negative breast cancer: validation of recommendations by the International TILs Working Group 2014. J Surg Oncol. 2016;114(1):17–21. https://doi.org/10.1002/jso.24275.

Article  CAS  PubMed  Google Scholar 

Ruan M, Tian T, Rao J, Xu X, Yu B, Yang W, et al. Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers. Diagn Pathol. 2018;13(1):66. https://doi.org/10.1186/s13000-018-0743-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajiri H, Takashima T, et al. Platelet–lymphocyte ratio as a useful predictor of the therapeutic effect of neoadjuvant chemotherapy in breast cancer. PLoS ONE. 2016;11(7):e0153459. https://doi.org/10.1371/journal.pone.0153459.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Onagi H, Horimoto Y, Sakaguchi A, Ikarashi D, Yanagisawa N, Nakayama T, et al. High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs. Breast Cancer Res. 2022;24(1):67. https://doi.org/10.1186/s13058-022-01563-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19(22):4224–37. https://doi.org/10.1200/JCO.2001.19.22.4224.

Article  PubMed  Google Scholar 

Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, van Rees DJ, et al. Neutrophils kill antibody-opsonized cancer cells by trogoptosis. Cell Rep. 2018;23(13):3946-59.e6. https://doi.org/10.1016/j.celrep.2018.05.082.

Article  CAS  PubMed  Google Scholar 

Hubert P, Heitzmann A, Viel S, Nicolas A, Sastre-Garau X, Oppezzo P, et al. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer Res. 2011;71(15):5134–43. https://doi.org/10.1158/0008-5472.CAN-10-4222.

Article  CAS  PubMed